SG10201806648TA - Compositions, uses and methods for treatment of metabolic disorders and diseases - Google Patents
Compositions, uses and methods for treatment of metabolic disorders and diseasesInfo
- Publication number
- SG10201806648TA SG10201806648TA SG10201806648TA SG10201806648TA SG10201806648TA SG 10201806648T A SG10201806648T A SG 10201806648TA SG 10201806648T A SG10201806648T A SG 10201806648TA SG 10201806648T A SG10201806648T A SG 10201806648TA SG 10201806648T A SG10201806648T A SG 10201806648TA
- Authority
- SG
- Singapore
- Prior art keywords
- growth factor
- fibroblast growth
- treatment
- methods
- diseases
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 abstract 6
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 abstract 6
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 6
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 6
- 230000004927 fusion Effects 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010030 glucose lowering effect Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
Abstract
COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders. [Figure 3A]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504128P | 2011-07-01 | 2011-07-01 | |
US201161515126P | 2011-08-04 | 2011-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201806648TA true SG10201806648TA (en) | 2018-09-27 |
Family
ID=47437648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201806648TA SG10201806648TA (en) | 2011-07-01 | 2012-06-29 | Compositions, uses and methods for treatment of metabolic disorders and diseases |
Country Status (27)
Country | Link |
---|---|
US (9) | US8951966B2 (en) |
EP (3) | EP3597666A3 (en) |
JP (2) | JP6254524B2 (en) |
KR (1) | KR102077721B1 (en) |
CN (3) | CN103649127B (en) |
AU (1) | AU2012279237B2 (en) |
BR (1) | BR112013033175B1 (en) |
CA (1) | CA2835607C (en) |
CL (1) | CL2013003416A1 (en) |
CO (1) | CO6940374A2 (en) |
DK (1) | DK2726511T3 (en) |
ES (1) | ES2748038T3 (en) |
HK (1) | HK1198297A1 (en) |
HR (1) | HRP20191713T1 (en) |
HU (1) | HUE045629T2 (en) |
IL (2) | IL229903B (en) |
LT (1) | LT2726511T (en) |
MX (1) | MX349869B (en) |
MY (1) | MY163674A (en) |
PE (1) | PE20141727A1 (en) |
PL (1) | PL2726511T3 (en) |
PT (1) | PT2726511T (en) |
RU (1) | RU2697762C2 (en) |
SG (1) | SG10201806648TA (en) |
UA (1) | UA118744C2 (en) |
WO (1) | WO2013006486A2 (en) |
ZA (2) | ZA201308421B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
EP2488643A4 (en) * | 2009-10-15 | 2013-07-03 | Hoffmann La Roche | Chimeric fibroblast growth factors with altered receptor specificity |
EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
PE20141727A1 (en) | 2011-07-01 | 2014-11-26 | Ngm Biopharmaceuticals Inc | COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES |
US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9283241B2 (en) * | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
AU2013370404B2 (en) * | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2014130659A1 (en) * | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US20160120959A1 (en) * | 2013-03-14 | 2016-05-05 | The Board Of Regents Of The University Of Oklahoma | Use of Klotho Nucleic Acids or Proteins for Treatment of Diabetes and Diabetes-Related Conditions |
US20150104494A1 (en) * | 2013-10-11 | 2015-04-16 | Ohio State Innovation Foundation | Methods for repair of ear canal tissue defects |
MX2016005101A (en) * | 2013-10-21 | 2017-01-09 | Salk Inst For Biological Studi | Mutated fibroblast growth factor (fgf) 1 and methods of use. |
WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
AU2014342630B2 (en) * | 2013-10-28 | 2020-11-05 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
CN106662577B (en) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | Binding proteins and methods of use thereof |
EP3104873B1 (en) | 2014-02-13 | 2019-09-04 | Technische Universität München | Fgf-8 for use in treating diseases or disorders of energy homeostasis |
WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
EP3194430A1 (en) | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
WO2016048995A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf19 truncations and mutants and uses thereof |
SG11201702757YA (en) * | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
EP3108893A1 (en) | 2015-06-25 | 2016-12-28 | Universite Claude Bernard - Lyon 1 | Novel therapeutic use of fgf19 |
EP3322736B1 (en) * | 2015-07-15 | 2021-09-01 | Prosit Sole Biotechnology (Beijing) Co., Ltd | Fusion polypeptides and methods of use |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
WO2017075260A1 (en) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
ES2871036T3 (en) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Method for treating bile acid-related disorders |
WO2017205517A1 (en) * | 2016-05-25 | 2017-11-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of secretory disorders |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN106279437B (en) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes |
CN107759694B (en) * | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | Bispecific antibody, preparation method and application thereof |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
IL306098A (en) * | 2017-05-24 | 2023-11-01 | Univ Barcelona Autonoma | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
US20200102361A1 (en) * | 2017-05-24 | 2020-04-02 | Universitat Autònoma De Barcelona | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
WO2019010314A1 (en) * | 2017-07-06 | 2019-01-10 | Yale University | Compositions and methods for treating or preventing endocrine fgf-linked diseases |
DK3678687T3 (en) * | 2017-09-04 | 2022-11-14 | 89Bio Ltd | MUTANT FGF-21 PEPTIDE CONJUGATES AND USES THEREOF |
KR102054561B1 (en) | 2017-11-22 | 2019-12-10 | 가천대학교 산학협력단 | Fusion protein of c2 domain and akt kinase domain fragment and use thereof |
KR102105623B1 (en) | 2017-11-22 | 2020-04-29 | 가천대학교 산학협력단 | Screening method of drug candidates for treating disease using interaction between calcium and phosphatidylinositol phosphate |
CN113603794B (en) * | 2018-01-11 | 2024-01-16 | 安源医药科技(上海)有限公司 | Synergistic bifunctional proteins for regulating blood glucose and lipids |
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
CN113227126A (en) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | Fibroblast growth factor 21(FGF21) gene therapy |
US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
CN113728013B (en) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN113735959B (en) * | 2021-03-12 | 2023-07-04 | 江南大学 | FGF analogue for treating NASH |
WO2024097875A1 (en) * | 2022-11-02 | 2024-05-10 | Shattuck Labs, Inc. | Fusion proteins for the treatment of nonalcoholic steatohepatitis |
Family Cites Families (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63502716A (en) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | How to enhance glycoprotein stability |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
JPH04503306A (en) | 1989-02-01 | 1992-06-18 | ザ・ジェネラル・ホスピタル・コーポレーション | Herpes simplex virus type 1 expression vector |
US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
ATE352612T1 (en) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | HOMOLOGOUS RECOMBINATION IN MAMMAL CELLS |
GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
ES2140359T1 (en) | 1993-06-14 | 2000-03-01 | Basf Ag | PRECISE CONTROL OF GENETIC EXPRESSION IN EUCARIOTIC CELLS THROUGH PROMOTERS RESPONDING TO TETACICLINE. |
EP0728202A4 (en) | 1993-11-12 | 1997-04-23 | Univ Case Western Reserve | Episomal expression vector for human gene therapy |
CA2117668C (en) | 1994-03-09 | 2005-08-09 | Izumu Saito | Recombinant adenovirus and process for producing the same |
US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
JP3770333B2 (en) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | Recombinant DNA virus and method for producing the same |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5695977A (en) | 1995-08-31 | 1997-12-09 | Genetic Information Research Institute | Site directed recombination |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
CA2264735C (en) | 1996-08-27 | 2008-01-29 | Chiron Corporation | Neisseria meningitidis serogroup b glycoconjugates and methods of using the same |
US20060246540A1 (en) | 1997-08-26 | 2006-11-02 | Ashkenazi Avi J | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020012961A1 (en) | 1999-04-15 | 2002-01-31 | Genentech, Inc. | Fibroblast growth factor- 19 |
US20020042367A1 (en) | 1997-11-25 | 2002-04-11 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US6806352B2 (en) | 1997-09-17 | 2004-10-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ATE447583T1 (en) | 1997-09-17 | 2009-11-15 | Genentech Inc | POLYPEPTIDES AND NUCLEIC ACIDS CODING THEREFOR |
US20030077654A1 (en) | 1997-09-17 | 2003-04-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030113718A1 (en) | 1997-09-17 | 2003-06-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040126852A1 (en) | 1997-11-25 | 2004-07-01 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
US20050026832A1 (en) | 1997-11-25 | 2005-02-03 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US20020155543A1 (en) | 1997-11-25 | 2002-10-24 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
WO2000060085A1 (en) | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
US7390879B2 (en) | 1999-06-15 | 2008-06-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7129072B1 (en) | 1999-08-30 | 2006-10-31 | New York University | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
AU7368100A (en) | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
US6797695B1 (en) | 1999-10-22 | 2004-09-28 | Kyoto University | Human FGF-20 gene and gene expression products |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
DE10160151A1 (en) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang |
EP1246843A1 (en) | 2000-01-05 | 2002-10-09 | ZymoGenetics, Inc. | Novel fgf homolog zfgf12 |
WO2001049849A1 (en) | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Novel fgf homolog zfgf11 |
US20010044525A1 (en) | 2000-01-05 | 2001-11-22 | Conklin Darrell C. | Novel FGF Homolog zFGF12 |
US20020081663A1 (en) | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
US20060160181A1 (en) | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
AU3976701A (en) | 2000-02-15 | 2001-08-27 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
US20030180312A1 (en) | 2000-02-22 | 2003-09-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1261638A2 (en) | 2000-03-08 | 2002-12-04 | Chiron Corporation | Human fgf-23 gene and gene expression products |
US20030105302A1 (en) | 2000-03-08 | 2003-06-05 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
WO2001072957A2 (en) | 2000-03-31 | 2001-10-04 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
US20030065140A1 (en) | 2000-04-03 | 2003-04-03 | Vernet Corine A.M. | Novel proteins and nucleic acids encoding same |
JP2002112772A (en) | 2000-07-10 | 2002-04-16 | Takeda Chem Ind Ltd | New polypeptide and its dna |
ATE461213T1 (en) | 2000-07-19 | 2010-04-15 | Advanced Res & Tech Inst | NEW FIBROBLAST GROWTH FACTOR (FGF23) AND METHODS OF USE |
CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US7115415B2 (en) | 2000-09-15 | 2006-10-03 | Genentech, Inc. | PRO9821 nucleic acids |
IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
WO2002041911A2 (en) | 2000-11-22 | 2002-05-30 | Bayer Corporation | Use of fgf-19 for inhibiting angiogenesis |
US20020151496A1 (en) | 2000-12-08 | 2002-10-17 | Bringmann Peter W. | Novel fibroblast growth factors |
DE10100587C1 (en) | 2001-01-09 | 2002-11-21 | Ribopharma Ag | Inhibiting expression of target genes, e.g. oncogenes, in cells, by introduction of complementary double-stranded oligoribonucleotide, after treating the cell with interferon |
DE10100588A1 (en) | 2001-01-09 | 2002-07-18 | Ribopharma Ag | Inhibiting expression of target genes, useful e.g. for treating tumors, by introducing into cells two double-stranded RNAs that are complementary to the target |
US20030125521A1 (en) | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO2003080803A2 (en) | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
WO2003103725A1 (en) | 2002-06-07 | 2003-12-18 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
ATE328906T1 (en) | 2002-06-28 | 2006-06-15 | Domantis Ltd | DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE |
US20050250684A1 (en) | 2002-09-18 | 2005-11-10 | Eli Lilly And Company Patent Division | Method for reducing morbidity and mortality in critically ill patients |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
DE602004011770T2 (en) | 2003-06-12 | 2009-02-05 | Eli Lilly And Co., Indianapolis | FUSION PROTEIN |
RS53476B (en) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Specific binding agents to hepatocyte growth factor |
WO2005061712A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
CN101659704A (en) | 2004-03-11 | 2010-03-03 | 弗雷泽纽斯卡比德国有限公司 | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
SI1751184T1 (en) | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fusion proteins |
WO2005118642A2 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
JP2006016323A (en) | 2004-06-30 | 2006-01-19 | Hiroshima Industrial Promotion Organization | Physiologically active biomaterial |
EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
DK1789442T3 (en) | 2004-09-02 | 2009-11-16 | Lilly Co Eli | Muteins of fibroblast growth factor 21 |
CN101724071A (en) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | Single domain antibodies against TNFRl and methods of use therefor |
ZA200704338B (en) | 2004-10-29 | 2009-03-25 | Genentech Inc | Novel gene disruptions, compositions and methods relating thereto |
US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
JP2008522617A (en) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | Fibroblast growth factor 21 mutein |
US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
UY29460A1 (en) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | NUCLEIC ACIDS FROM UNION TO GHRELIN |
DE602006010874D1 (en) | 2005-07-22 | 2010-01-14 | Five Prime Therapeutics Inc | COMPOSITIONS AND METHODS OF TREATING DISEASES WITH FGFR FUSION PROTEINS |
CA2620082A1 (en) | 2005-08-24 | 2007-03-01 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
WO2007091958A1 (en) | 2006-02-10 | 2007-08-16 | Dermagen Ab | Novel antimicrobial peptides and use thereof |
US20100055730A1 (en) | 2006-05-05 | 2010-03-04 | Anny Usheva-Simidjiyska | Methods for the Diagnosis and Treatment of Female Infertility Using Molecular Markers |
WO2008021196A2 (en) | 2006-08-09 | 2008-02-21 | The Mclean Hospital Corporation | Methods and compositions for the treatment of medical disorders |
CA2661332A1 (en) | 2006-09-01 | 2008-03-13 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
WO2008052796A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
WO2008085879A2 (en) | 2007-01-03 | 2008-07-17 | California Stem Cell, Inc. | Stem cell growth media and methods of making and using same |
BRPI0809583B1 (en) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Modified fgf-21 polypeptide, composition comprising the same, method for producing said fgf-21 polypeptide, and cell comprising a polynucleotide |
PT2550972T (en) | 2007-04-02 | 2018-05-02 | Genentech Inc | A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
US20120142546A1 (en) | 2007-12-10 | 2012-06-07 | The Johns Hopkins University | Hypomethylated genes in cancer |
EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
US20090226459A1 (en) | 2008-01-29 | 2009-09-10 | Cold Spring Harbor Laboratory | Role of fgf-19 in cancer diagnosis and treatment |
NZ579566A (en) | 2008-03-19 | 2013-01-25 | Ambrx Inc | Modified fgf-21 polypeptides and their uses |
US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
AU2009226246A1 (en) | 2008-03-21 | 2009-09-24 | Podiceps B.V. | Diagnostic of pre-symptomatic metabolic syndrome |
CN101591653B (en) | 2008-05-27 | 2013-07-31 | 中国人民解放军军事医学科学院野战输血研究所 | Low-expression CYP7A1 hepatic cell and constructing method thereof |
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
JP2011525241A (en) | 2008-06-18 | 2011-09-15 | アボット・ラボラトリーズ | PlGF-1 companion diagnostic method and product |
FR2933702A1 (en) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR |
WO2010006214A1 (en) | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Fgf-21 neutralizing antibodies and their uses |
AU2009279806B2 (en) | 2008-08-04 | 2015-04-30 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
MX341149B (en) | 2008-10-10 | 2016-08-09 | Amgen Inc | Fgf21 mutants and uses thereof. |
WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
US20110268794A1 (en) | 2009-01-09 | 2011-11-03 | Camilleri Michael L | Methods and materials for delivering bile acids |
WO2010080976A1 (en) | 2009-01-09 | 2010-07-15 | Sdg, Inc. (An Ohio Corporation) | Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments |
US20100274362A1 (en) | 2009-01-15 | 2010-10-28 | Avner Yayon | Cartilage particle tissue mixtures optionally combined with a cancellous construct |
DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
CA2760674A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
PE20120358A1 (en) | 2009-05-05 | 2012-04-26 | Amgen Inc | FGF21 MUTANTS AND USES OF THEM |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
US10241093B2 (en) | 2009-05-28 | 2019-03-26 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
US20120076729A1 (en) | 2009-06-04 | 2012-03-29 | Novartis Ag | Methods of treating cancers |
EP2440235A1 (en) | 2009-06-11 | 2012-04-18 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
AU2010262927A1 (en) | 2009-06-17 | 2012-01-19 | Amgen Inc. | Chimeric FGF19 polypeptides and uses thereof |
CN101993485B (en) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof |
EP2488643A4 (en) | 2009-10-15 | 2013-07-03 | Hoffmann La Roche | Chimeric fibroblast growth factors with altered receptor specificity |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
US20110312881A1 (en) | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
EP2460527A1 (en) | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
MX2012011986A (en) | 2010-04-15 | 2013-03-05 | Amgen Inc | Human fgf receptor and î²-klotho binding proteins. |
EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
JP6069198B2 (en) | 2010-07-20 | 2017-02-01 | ノヴォ ノルディスク アー/エス | FGF21 compound modified at the N-terminus |
US20130216608A1 (en) | 2010-09-09 | 2013-08-22 | Trifoilium Aps | Airway Administration of Angiogenesis Inhibitors |
EA201370076A1 (en) | 2010-09-22 | 2013-08-30 | Амген Инк. | IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION |
CN102464712A (en) | 2010-11-11 | 2012-05-23 | 重庆富进生物医药有限公司 | Deletion human fibroblast growth factor 21 variant and conjugate thereof |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
JP5613547B2 (en) | 2010-12-14 | 2014-10-22 | 株式会社スクウェア・エニックス | Task-based parallel programming language |
AU2011348202A1 (en) | 2010-12-22 | 2013-07-04 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides |
JP5850435B2 (en) | 2010-12-24 | 2016-02-03 | 国立研究開発法人産業技術総合研究所 | Accurate and sensitive measurement method for human FGF19 activity and human FGF19 activity regulator |
JP5977814B2 (en) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
AU2012254160A1 (en) | 2011-05-10 | 2013-11-21 | Amgen Inc. | Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho |
ES2628385T3 (en) | 2011-05-16 | 2017-08-02 | F. Hoffmann-La Roche Ag | FGFR1 agonists and use procedures |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
SG195191A1 (en) | 2011-06-08 | 2013-12-30 | Denovo Biopharma Hangzhou Ltd Co | Methods and compositions of predicting activity of retinoid x receptor modulator |
WO2012177481A2 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
PE20141727A1 (en) | 2011-07-01 | 2014-11-26 | Ngm Biopharmaceuticals Inc | COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES |
EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
US20140213512A1 (en) | 2011-08-31 | 2014-07-31 | Amgen Inc. | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 |
TW201315742A (en) | 2011-09-26 | 2013-04-16 | Novartis Ag | Dual fuction proteins for treating metabolic disorders |
UY34346A (en) | 2011-09-26 | 2013-04-30 | Novartis Ag | FUSION PROTEINS TO TREAT METABOLIC DISORDERS |
AR087973A1 (en) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS |
CN103127503B (en) | 2011-11-23 | 2017-11-10 | 上海医学生命科学研究中心有限公司 | The purposes of antagonism and/or blocking IL 6/IL 6R/gp130 signal paths in anti-liver cancer and anti-treatment |
MX2014008699A (en) | 2012-01-18 | 2014-11-21 | Genentech Inc | Methods of using fgf19 modulators. |
US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
JP2013194049A (en) | 2012-03-23 | 2013-09-30 | Kazuo Todokoro | Composition and method for amplifying human hematopoietic stem cell |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2844273B1 (en) | 2012-04-16 | 2018-01-31 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Klotho variant polypeptides and uses thereof in therapy |
PE20142432A1 (en) | 2012-05-15 | 2015-01-22 | Lilly Co Eli | THERAPEUTIC USES OF PROTEINS FROM THE FIBROBLAST GROWTH FACTOR 21 |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
MX2014015258A (en) | 2012-06-11 | 2015-03-05 | Lilly Co Eli | Fibroblast growth factor 21 variants. |
TWI513705B (en) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | Fibroblast growth factor 21 proteins |
ES2916220T3 (en) | 2012-07-11 | 2022-06-29 | Blueprint Medicines Corp | Fibroblast growth factor receptor inhibitors |
AR092076A1 (en) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | HOMODIMERIC PROTEINS |
BR112015004734A2 (en) | 2012-09-07 | 2017-11-21 | Sanofi Sa | fusion proteins to treat a metabolic syndrome |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9789160B2 (en) | 2013-03-14 | 2017-10-17 | Georgetown University | Treatments for lowering glucose levels using FGF binding protein 3 |
WO2014152089A1 (en) | 2013-03-14 | 2014-09-25 | Georgetown University | Compositions and treatments of metabolic disorders using fgf binding protein 3 |
WO2014152090A1 (en) | 2013-03-14 | 2014-09-25 | Georgetown University | Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19 |
WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
US9835631B2 (en) | 2013-04-15 | 2017-12-05 | Nordic Bioscience A/S | Combined biomarker measurement of fibrosis |
MX2016005101A (en) | 2013-10-21 | 2017-01-09 | Salk Inst For Biological Studi | Mutated fibroblast growth factor (fgf) 1 and methods of use. |
AU2014342630B2 (en) | 2013-10-28 | 2020-11-05 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
CN106662577B (en) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | Binding proteins and methods of use thereof |
US20170173114A1 (en) | 2014-05-07 | 2017-06-22 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2016048995A2 (en) | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf19 truncations and mutants and uses thereof |
SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
EP3108893A1 (en) | 2015-06-25 | 2016-12-28 | Universite Claude Bernard - Lyon 1 | Novel therapeutic use of fgf19 |
JP6903640B2 (en) | 2015-09-24 | 2021-07-14 | ジェネンテック, インコーポレイテッド | How to treat epilepsy |
ES2871036T3 (en) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Method for treating bile acid-related disorders |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
CA3034435A1 (en) | 2016-08-29 | 2018-03-08 | Lei Ling | Methods for treatment of bile acid-related disorders |
KR102340750B1 (en) | 2017-03-03 | 2021-12-21 | 에이치엘비테라퓨틱스 주식회사 | Stabilized topical composition comprising thymosin beta 4 as an active ingredient |
CN108619490A (en) | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | A kind of new application of the people source fibroblast growth factor of long-actingization mutation |
WO2018195390A1 (en) | 2017-04-21 | 2018-10-25 | Ngm Biopharmaceuticals, Inc. | Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides |
WO2019010314A1 (en) | 2017-07-06 | 2019-01-10 | Yale University | Compositions and methods for treating or preventing endocrine fgf-linked diseases |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
WO2020176703A1 (en) | 2019-02-28 | 2020-09-03 | Ngm Biopharmaceuticals, Inc. | Non-invasive biomarkers for use in the treatment of non-alcoholic steatohepatitis and other bile acid-related disorders |
WO2020214753A1 (en) | 2019-04-17 | 2020-10-22 | Ngm Biopharmaceuticals, Inc. | Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
-
2012
- 2012-06-29 PE PE2013002902A patent/PE20141727A1/en active IP Right Grant
- 2012-06-29 EP EP19181314.6A patent/EP3597666A3/en not_active Withdrawn
- 2012-06-29 CN CN201280032887.1A patent/CN103649127B/en active Active
- 2012-06-29 WO PCT/US2012/045087 patent/WO2013006486A2/en active Application Filing
- 2012-06-29 CA CA2835607A patent/CA2835607C/en active Active
- 2012-06-29 EP EP23192402.8A patent/EP4306165A3/en active Pending
- 2012-06-29 MX MX2013013833A patent/MX349869B/en active IP Right Grant
- 2012-06-29 PT PT128077864T patent/PT2726511T/en unknown
- 2012-06-29 US US13/538,705 patent/US8951966B2/en active Active
- 2012-06-29 DK DK12807786.4T patent/DK2726511T3/en active
- 2012-06-29 EP EP12807786.4A patent/EP2726511B1/en active Active
- 2012-06-29 KR KR1020147002684A patent/KR102077721B1/en active IP Right Grant
- 2012-06-29 HU HUE12807786A patent/HUE045629T2/en unknown
- 2012-06-29 LT LT12807786T patent/LT2726511T/en unknown
- 2012-06-29 SG SG10201806648TA patent/SG10201806648TA/en unknown
- 2012-06-29 MY MYPI2013004719A patent/MY163674A/en unknown
- 2012-06-29 CN CN202110931961.4A patent/CN113683705A/en active Pending
- 2012-06-29 UA UAA201400875A patent/UA118744C2/en unknown
- 2012-06-29 AU AU2012279237A patent/AU2012279237B2/en active Active
- 2012-06-29 ES ES12807786T patent/ES2748038T3/en active Active
- 2012-06-29 CN CN201511029485.8A patent/CN105601748B/en active Active
- 2012-06-29 PL PL12807786T patent/PL2726511T3/en unknown
- 2012-06-29 BR BR112013033175-5A patent/BR112013033175B1/en active IP Right Grant
- 2012-06-29 JP JP2014519191A patent/JP6254524B2/en active Active
- 2012-06-29 RU RU2014103487A patent/RU2697762C2/en active
-
2013
- 2013-11-08 ZA ZA2013/08421A patent/ZA201308421B/en unknown
- 2013-11-28 CL CL2013003416A patent/CL2013003416A1/en unknown
- 2013-12-10 IL IL229903A patent/IL229903B/en unknown
- 2013-12-27 CO CO13300927A patent/CO6940374A2/en unknown
-
2014
- 2014-11-06 HK HK14111250.6A patent/HK1198297A1/en unknown
-
2015
- 2015-02-06 US US14/616,401 patent/US9089525B1/en active Active
- 2015-06-18 US US14/743,851 patent/US9580483B2/en active Active
- 2015-11-06 ZA ZA2015/08231A patent/ZA201508231B/en unknown
- 2015-12-29 US US14/983,280 patent/US9670260B2/en active Active
- 2015-12-29 US US14/983,324 patent/US9751924B2/en active Active
-
2017
- 2017-06-12 JP JP2017115205A patent/JP6634402B2/en active Active
- 2017-08-01 US US15/666,402 patent/US10413590B2/en active Active
-
2018
- 2018-06-25 US US16/017,759 patent/US11065302B2/en active Active
-
2019
- 2019-09-20 HR HRP20191713TT patent/HRP20191713T1/en unknown
-
2020
- 2020-05-05 IL IL274469A patent/IL274469A/en unknown
-
2021
- 2021-06-23 US US17/356,070 patent/US20220088140A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/453,182 patent/US20240050530A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201806648TA (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
WO2014085365A3 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
MX2021006856A (en) | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases. | |
WO2015183890A3 (en) | Methods and compositions for the treatment of metabolic disorders and diseases | |
TN2014000110A1 (en) | Dual function proteins for treating metabolic disorders | |
TN2014000109A1 (en) | Fusion proteins for treating metabolic disorders | |
MX2013005639A (en) | Methods of treating fgf21-associated disorders. | |
PH12014502766A1 (en) | Fibroblast growth factor 21 proteins | |
PH12014502537A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
TW201129373A (en) | Methods and compositions using FGF23 fusion polypeptides | |
PH12015500194A1 (en) | Fusion proteins for treating a metabolic syndrome | |
MX2014015258A (en) | Fibroblast growth factor 21 variants. | |
TN2014000096A1 (en) | Fibroblast growth factor 21 variants | |
NZ584827A (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
MX346002B (en) | Anti-vegf antibodies and their uses. | |
NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
WO2006105315A3 (en) | Compositions and methods for regulating inflammatory responses | |
GB201119261D0 (en) | Morus extracts rich in n-acids of imino sugars and or pipecolic acids | |
TW200738752A (en) | Modulation of MDL-1 activity for treatment of inflammatory disease | |
WO2012078060A3 (en) | Peptide preparations and peptides with antitumour activity | |
TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders |